SEHK:2228Life Sciences
XtalPi Holdings (SEHK:2228) Advances AI-Driven Cancer Therapy With Regulatory Clearance
XtalPi Holdings (SEHK:2228) recently announced a significant milestone as its next-generation PRMT5 inhibitor, PEP08, received regulatory approvals to begin Phase 1 clinical trials for solid tumors. This development underscores the company's advanced capabilities in drug discovery, likely contributing to the impressive 65% rise in its stock price over the last quarter. Alongside broader tech market gains, highlighted by the S&P 500 and Nasdaq reaching new highs, XtalPi's earnings reports...